Xeris Biopharma (NASDAQ:XERS) Given Outperform Rating at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Xeris Biopharma (NASDAQ:XERS) in a report published on Friday,Benzinga reports. They currently have a $21.00 price objective on the stock, up from their previous price objective of $18.00.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Piper Sandler restated a “neutral” rating and set a $12.00 price target (up from $8.00) on shares of Xeris Biopharma in a research note on Friday. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Leerink Partners upped their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Finally, HC Wainwright increased their target price on shares of Xeris Biopharma from $10.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $16.20.

Xeris Biopharma Stock Up 16.2%

Xeris Biopharma stock traded up $2.12 during mid-day trading on Friday, hitting $15.20. The company’s stock had a trading volume of 7,895,311 shares, compared to its average volume of 2,146,978. The firm’s 50 day moving average is $9.62 and its 200 day moving average is $7.62. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The company has a market cap of $2.77 billion, a PE ratio of -303.94 and a beta of 0.61. Xeris Biopharma has a 52-week low of $5.25 and a 52-week high of $15.21.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The firm had revenue of $107.23 million for the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. On average, analysts anticipate that Xeris Biopharma will post 0.07 earnings per share for the current year.

Insider Buying and Selling

In other Xeris Biopharma news, insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $51,150.00. Following the completion of the sale, the insider owned 1,346,053 shares of the company’s stock, valued at $13,770,122.19. This represents a 0.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of the stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $12.49, for a total value of $312,250.00. Following the transaction, the insider owned 1,559,208 shares in the company, valued at approximately $19,474,507.92. This trade represents a 1.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 173,332 shares of company stock worth $1,721,471. 4.35% of the stock is currently owned by insiders.

Institutional Trading of Xeris Biopharma

Large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Xeris Biopharma in the 2nd quarter valued at $115,042,000. Legal & General Group Plc bought a new position in Xeris Biopharma in the 2nd quarter worth $15,941,000. Parkman Healthcare Partners LLC bought a new position in Xeris Biopharma in the 2nd quarter worth $14,316,000. Bank of America Corp DE acquired a new position in Xeris Biopharma during the 2nd quarter worth $11,065,000. Finally, Vilga Financial Planning LLC acquired a new position in Xeris Biopharma during the 3rd quarter worth $10,134,000. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma News Roundup

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
• Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
• Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
• Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.